基本信息
文件名称:雷美替胺(?Ramelteon)片的CTD资料(PMDA).pdf
文件大小:3.3 MB
总页数:98 页
更新时间:2025-06-03
总字数:约39.37万字
文档摘要

ReportontheDeliberationResults

February5,2010

EvaluationandLicensingDivision,PharmaceuticalandFoodSafetyBureau

MinistryofHealth,LabourandWelfare

[Brandname]RozeremTablets8mg

[Non-proprietaryname]Ramelteon(JAN*)

[Applicant]TakedaPharmaceuticalCompanyLimited

[Dateofapplication]February29,2008

[Resultsofdeliberation]

InthemeetingheldonJanuary29,2010,theFirstCommitteeonNewDrugsconcludedthattheproduct

maybeapprovedandthatthisresultshouldbepresentedtothePharmaceuticalAffairsDepartmentofthe

PharmaceuticalAffairsandFoodSanitationCouncil.

Theproductisnotclassifiedasabiologicalproductoraspecifiedbiologicalproduct,there-examination

periodis8years,andthedrugsubstanceisclassifiedasapowerfuldrugandthedrugproductisnot

classifiedasapoisonousdrugorapowerfuldrug.

*JapaneseAcceptedName(modifiedINN)

ThisEnglishversionoftheJapanesereviewreportisintendedtobeareferencematerialtoprovideconvenience

forusers.IntheeventofinconsistencybetweentheJapaneseoriginalandthisEnglishtranslation,theformer

shallprevail.ThePMDAwillnotberesponsibleforanyconsequenceresultingfromtheuseofthisEnglishversion.

ReviewReport

January15,2010

PharmaceuticalsandMedicalDevicesAgency

TheresultsofaregulatoryreviewconductedbythePharmaceuticalsandMedicalDevicesAgencyonthe

followingpharmaceuticalproductsubm